| Biologic Therapy |
1 |
1 |
| CAR-T |
0 |
1 |
| T-Lymphocyte |
0 |
0.64 |
| Toxicology |
0 |
0.39 |
| Refractory |
0 |
0.21 |
| Patient Safety |
0 |
0.19 |
| Adverse Effects |
0 |
0.14 |
| Cancer |
0 |
0.14 |
| Stem Cell Research and Therapy |
0 |
0.13 |
| Gene Therapy |
0 |
0.11 |
| Anaphylaxis |
0 |
0.1 |
| Graft Versus Host Disease and Transplant Complications |
0 |
0.1 |
| Acute Leukemia |
0 |
0.07 |
| Bone Marrow Transplant |
0 |
0.07 |
| Europe |
0 |
0.07 |
| Acute Lymphoblastic Leukemia |
0 |
0.05 |
| B-Cell Lymphoma |
0 |
0.05 |
| Bone Marrow |
0 |
0.05 |
| Graft Versus Host Disease |
0 |
0.05 |
| Neutropenia |
0 |
0.05 |
| Thrombocytopenia |
0 |
0.05 |
| Anemia |
0 |
0.04 |
| Antigens |
0 |
0.04 |
| Bone |
0 |
0.04 |
| Corticosteroids |
0 |
0.04 |
| CRISPR |
0 |
0.04 |
| Cytokines |
0 |
0.04 |
| Dorsum |
0 |
0.04 |
| Food and Drug Administration (FDA) |
0 |
0.04 |
| Graft |
0 |
0.04 |
| Hematology |
0 |
0.04 |
| Hypogammaglobulinemia |
0 |
0.04 |
| Leukemia |
0 |
0.04 |
| Lymphoma |
0 |
0.04 |
| Neurotoxicity |
0 |
0.04 |
| Receptors |
0 |
0.04 |
| Steroids |
0 |
0.04 |
| Texas |
0 |
0.04 |
| Transplantation |
0 |
0.04 |
| Tumor |
0 |
0.04 |